By 2050 antimicrobial resistant infections are forecast to be a leading cause of death. This project exploits the tremendous biosynthetic potential of marine sponge-associated Streptomyces to identify novel therapeutics against pathogens like enterohemorrhagic and uropathogenic E. coli. Crude extracts will be obtained from Streptomyces, gene expression and virulence assays will be performed to test efficacy of the extracts before they are fractionated and characterised using analytical chemistry approaches under the supervision of Dr Boylan in TBSI. Genomic analysis will be used to identify the Streptomyces biosynthetic gene clusters responsible for producing active compounds.